

Schlaganfall

Diagnostische und therapeutische Fortschritte 2003 und 2004

Hans Christoph Diener, Elmar Busch und Christian Weimar, Essen*

Literatur

- Diener HC, Busse O, Hacke W, Ringelstein WB, et al. Primäre und sekundäre Prävention der zerebralen Ischämie. In: Diener HC, Hacke W, Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg). Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme, 2002:109–24.
- Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. *Lancet* 1997;350:1277–83.
- Petitti DB, Sidney S, Quesenberry CP, Bernstein A. Ischemic stroke and use of estrogen and estrogen/progesterone as hormone replacement therapy. *Stroke* 1997;29:23–8.
- Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, et al. for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. *JAMA* 2003;289:2673–84.
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:231–3.
- Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, et al. Increased risk of stroke in hypertensive women using hormone therapy. *Arch Neurol* 2003;60:1379–84.
- Viscoli CM, Brass LM, Kernan WN, Sarrel PM, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. *N Engl J Med* 2001;345:1243–9.
- Lawes C, Bennett D, Feigin V, Rodgers A. Blood pressure and stroke: an overview of published reviews. *Stroke* 2004;35:776–85.
- Chobanian A, Bakris G, Black H, Cushman W, et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA* 2003;289:2560–72.
- Lewington S, Clarke R, Qizilbash N, Peto R, et al., Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002;360:1903–13.
- Psaty B, Lumley T, Furberg C, Schellenbaum G, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. *JAMA* 2003;289:2534–44.
- Dahlof B, Devereux RB, Kjeldsen SE, Julius S, et al. and the LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:995–1003.
- Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. *Lancet* 1999;354:407–13.
- McIlroy SP, Dynan KB, Lawson JT, Patterson CC, et al. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. *Stroke* 2002;33:2351–6.
- Perry I, Refsum H, Morris R, Ebrahim S, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged british men. *Lancet* 1995;346:1395–8.
- Ridker PM, Manson JE, Buring JE, Shih J, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. *JAMA* 1999;281:1817–21.
- Voko Z, Hollander M, Hofman A, Koudstaal P, et al. Dietary antioxidants and the risk of ischemic stroke. The Rotterdam Study. *Neurology* 2003;61:1273–5.
- Vivekananthan DP, Penn MS, Sapp SK, Hsu A, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. *Lancet* 2003;361:2017–23.
- Toole J, Malinow M, Chambless L, Spence J, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA* 2004;291:565–75.
- Bowman T, Sesso H, Ma J, Kurth T, et al. Cholesterol and the risk of ischemic stroke. *Stroke* 2003;34:2930–4.
- Shahar E, Chambless L, Rosamond W, Boland L, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. *Stroke* 2003;34:623–31.
- Wilson PWF, Hoeg JM, D'Agostino RB, Silbershatz H, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. *N Engl J Med* 1997;337:516–22.
- Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. *Stroke* 1997;28:946–50.
- Sever P, Dahlof B, Poulter N, Wedel H, et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003;361:1149–58.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:7–22.
- Collins R, Armitage J, Parish S, Sleight P, et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003;361:2005–16.
- Reynolds K, Lewis LB, Nolen JD, Kinney GL, et al. Alcohol consumption and risk of stroke: a meta-analysis. *JAMA* 2003;289:579–88.
- Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. *BMJ* 2002;325:1022–5.
- Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. *Stroke* 2001;32:803–8.
- Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. *Stroke* 2002;33:2722–7.
- Van Walraven C, Hart RG, Singer DE, Laupacis A, et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. *JAMA* 2002;288:2441–8.
- The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke prevention in atrial fibrillation III study. *JAMA* 1998;279:1273–7.
- Go A, Hylek E, Chang Y, Phillips K, et al.

**Dieser Artikel erscheint in leicht modifizierten Versionen in den Zeitschriften Arzneimitteltherapie und Aktuelle Neurologie*

Prof. Dr. med. Hans Christoph Diener, Priv.-Doz. Dr. med. Elmar Busch, Priv.-Doz. Dr. med. Christian Weimar, Universitätsklinik für Neurologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122 Essen, E-Mail: h.diener@uni-essen.de

- Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? *JAMA* 2003;290:2685–92.
34. Hylek E, Go A, Chang Y, Jensvold N, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med* 2003;349:1019–26.
 35. Eriksson UG, Bredberg U, Gislén K, Johansson LC, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects. *Eur J Clin Pharmacol* 2003;59:35–43.
 36. Johansson LC, Frison F, Logren U, Fager G, et al. The influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. *Clin Pharmacokinetics* 2003;42:382–91.
 37. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. *Lancet* 2003;362:1691–8.
 38. Caress J, Cartwright M, Donofrio P, Peacock JJ. The clinical features of 16 cases of stroke associated with administration of IVIg. *Neurology* 2003;60:1822–4.
 39. Weimar C, Glahn J, von Reutern GM, Kloth A, et al. Behandlung des ischämischen Schlaganfalls in 14 neurologischen Stroke Units. *Nervenarzt* 2002;73:342–8.
 40. German Stroke Study Collaboration. Predicting outcome after acute ischemic stroke: an external validation of prognostic models. *Stroke* 2004;62:581–5.
 41. Sulter G, Elting JW, Langedijk M, Maurits NM, et al. Admitting acute ischemic stroke patients to a stroke care monitoring unit versus a conventional stroke unit: a randomized pilot study. *Stroke* 2003;34:101–4.
 42. Furlan A, Higashida R, Wechsler L, Gent M, et al. for the PROACT Investigators. Intra-arterial prourokinase for acute ischemic stroke – The PROACT II Study: A randomized controlled trial. *JAMA* 1999;282:2003–11.
 43. Heuschmann P, Berger K, Misselwitz B, Hermanek P, et al. German Stroke Registers Study Group, Competence Net Stroke. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. *Stroke* 2003;34:1106–13.
 44. Schenkel J, Weimar C, Knoll T, Haberl RL, et al. R1 – Systemic thrombolysis in German stroke units. The experience from the German Stroke data bank. *J Neurol* 2003;250:320–4.
 45. Graham D. Tissue plasminogen activator for acute ischemic stroke in clinical practice. A meta-analysis of safety data. *Stroke* 2003;34:2847–50.
 46. Schmuelling S, Rudolf J, Strotmann-Tack T, Grond M, et al. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. *Cerebrovasc Dis* 2003;16:183–90.
 47. Arnold M, Nedeltchev K, Mattle H, Loher T, et al. Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. *J Neurol Neurosurg Psychiatry* 2003;74:739–42.
 48. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke – A randomized, double-blind, placebo-controlled, dose-escalation study. *Stroke* 2000;31:601–9.
 49. Schrader J, Lüders S, Kulschewski A, Berger J, et al. on behalf of the ACCESS Study Group. Evaluation of acute candesartan cilexetil therapy in stroke survivors. *Stroke* 2003;34:1699–1703.
 50. Lees K, Diener HC. Neuroprotection in stroke therapy. In: Edvinsson L, Krause DN (eds.). *Cerebral blood flow and metabolism*. Philadelphia: Lippincott, Williams & Wilkins, 2002:452–6.
 51. Diener H. Current status of neuroprotective drugs in stroke. *Europ J Anaesthesiol* 2000;17:55–8.
 52. Muir K, Lees K, Ford I, Davis S, Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. *Lancet* 2004;363:439–445.
 53. Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. *Stroke* 1998;29:918–23.
 54. Krams M, Lees KR, Hacke W, Grieve AP, et al. for the ASTIN Study Investigators. Acute stroke therapy by inhibition of neutrophils (ASTIN). An adaptive dose-response study of UK-279,276 in acute ischemic stroke. *Stroke* 2003;34:2543–8.
 55. Zetterling M, Carlstrom C, Konrad P. Internal carotid artery dissection. *Acta Neurol Scand* 2000;101:1–7.
 56. Touzé E, Gauvrit J-Y, Moulin T, Meder J-F, et al. for the Multicenter Survey on History of Cervical Artery Dissection. Risk of stroke and recurrent dissection after a cervical artery dissection. A multicenter study. *Neurology* 2003;61:1347–51.
 57. Dziejewski R, Konrad C, Dräger B, Evers S, et al. Cervical artery dissection – clinical features, risk factors, therapy and outcome in 126 patients. *J Neurol* 2003;250:1179–84.
 58. Kremer C, Mosso M, Georgiadis D, Stockli E, et al. Carotid dissection with permanent and transient occlusion or severe stenosis: Long-term outcome. *Neurology* 2003;60:271–5.
 59. Beletsky V, Nadareishvili Z, Lynch J, Shuaib A, et al. for the Canadian Stroke Consortium. Cervical arterial dissection. Time for a therapeutic trial? *Stroke* 2003;34:2856–60.
 60. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. *Stroke* 2003;34:2741–9.
 61. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001;358:1033–41.
 62. Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease. A randomized controlled trial. *Stroke* 2003;34:2333–8.
 63. Chapman N, Huxley R, Anderson CS, Bousser M, et al. for the Writing Committee for the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. *Stroke* 2004;35:116–21.
 64. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. *J Neurol Neurosurg Psychiatry* 1999;65:255.
 65. Diener HC, Cuhna L, Forbes C, Sivenius J, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996;143:1–13.
 66. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996;348:1329–39.
 67. Alberts M, Bergman D, Molner E, Jovanovic B, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. *Stroke* 2004;35:175–8.
 68. Gent M, Blakely JA, Easton JD, Ellis DJ, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. *Lancet* 1989;i:1215–20.
 69. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke. *N Engl J Med* 1989;321:501–7.
 70. Gorelick P, Richardson D, Kelly M, Ruland S, et al. for the African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. *JAMA* 2003;289:2947–57.
 71. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, et al. for the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. *Stroke* 2004;35:528–32.
 72. De Schryver E, Algra A, van Gijn J. Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. *Stroke* 2003;34:2072–80.
 73. De Schryver E, for the ESPRIT Study Group. Dipyridamole in stroke prevention. Effect of dipyridamole on blood pressure. *Stroke* 2003;34:2339–42.
 74. Hamann GF, Weimar C, Glahn J, Busse O, et al. for the German Stroke Data Bank. Adherence to secondary stroke prevention strategies – results from the German Stroke Data Bank. *Cerebrovasc Dis* 2003;15:282–8.
 75. Topol EJ, Easton JD, Harrington R, Amarenco P, et al. on Behalf of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antago-

- nist Itrafiban in coronary and cerebrovascular disease. *Circulation* 2003;108:16–23.
76. Levine S, Brey R, Tilley B, Thompson J, et al. for the APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. *JAMA* 2004;291:576–84.
77. Mohr JP, Thompson JL, Lazar RM, Levin B, et al. for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med* 2001;345:1444–51.
78. Orgogozo J, Rigaud A, Stoffler A, Mobius H, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). *Stroke* 2002;33:1834–9.
79. Wilcock G, Möbius HJ, Stöffler A, on behalf of the MMM 500 Group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). *Int J Psychopharmacol* 2002;17:297–305.
80. Wilkinson D, Doody R, Helme R, Taubmann K, et al., and the Donepezil 308 Study Group. Donepezil in vascular dementia. A randomized, placebo-controlled study. *Neurology* 2003;61:479–86.
81. Black S, Roman GC, Geldmacher DS, Salloway S, et al., and the Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. *Stroke* 2003;34:2323–30.
82. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. *Lancet* 2002;359:1283–90.